You are here

Encouraging results for PD-1 inhibition in gastric cancer

Smyth EC, Cunningham D.

Lancet Oncol. 2016 June [Epub ahead of print]

Summary


The prognosis for advanced gastric cancer is poor: less than 10–15% of patients with metastases live for more than 2 years. Trastuzumab and ramucirumab have resulted in modest improvements in overall survival for patients with HER2-positive gastric cancer and in the second-line setting, respectively.1–2 However, these drugs are notable for their success in a field in which there have been many failures.1–4 Within this challenging therapeutic context, the results of the KEYNOTE-012 study by Kei Muro and colleagues5 are promising.


Search this site

Search form

ECCO2017 symposium webcast: Treatment evolution in advanced GI malignancies

Welcome and introduction - Florian Lordick

E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Featured Content

New Book Content


This online Resource Centre has been sponsored by Lilly Oncology

Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.

Share